U of Florida and Penn Ink Licensing Deal for Gene Therapy to Treat Retinal Disease (Tech Transfer eNews Blog)

Biotech company Ophthotech Corporation has entered into an exclusive global license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania (Penn) to commercialize a treatment for a disease that causes blindness.

The licensed technology is an adeno-associated virus (AAV) gene therapy to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease characterized by progressive and severe loss of vision leading to blindness. Proof-of-concept studies of the therapy have shown promising results in a canine disease model, and Ophthotech plans to launch a Phase 1/2 clinical trial in early 2020.

Learn more about U of Florida and Penn Ink Licensing Deal for Gene Therapy to Treat Retinal Disease.